Table 2 Uptake of options by country

From: International trends in the uptake of cancer risk reduction strategies in women with a BRCA1 or BRCA2 mutation

Variables

Austria

Canada

China

France

Israel

Italy

Holland

Norway

Poland

USA

All

 

N1 = 127

N1 = 1780

N1 = 30

N1 = 30

N1 = 193

N1 = 42

N1 = 85

N1 = 408

N1 = 2054

N1 = 1474

N1 = 6223

 

N2 = 71

N2 = 1005

N2 = 8

N2 = 4

N2 = 107

N2 = 20

N2 = 55

N2 = 187

N2 = 1182

N2 = 774

N2 = 3413

 

N3 = 51

N3 = 623

N3 = 5

N3 = 3

N3 = 102

N3 = 18

N3 = 37

N3 = 107

N3 = 1129

N3 = 388

N3 = 2463

Oophorectomy1

  All

77(60.6)

1278(71.8)

11(36.7)

25(83.3)

130(67.4)

22(52.4)

55(64.7)

260(63.7)

1041(50.7)

1124 (76.3)

4023(64.7)

  <2009

77(60.6)

914(73.5)

NA

25(83.3)

130(67.4)

22(52.4)

55(64.7)

252(65.5)

785(52.4)

814(77.5)

3074(66.1)

  >=2009

0

364(67.9)

11(36.7)

NA

NA

NA

NA

8(34.8)

256(46.0)

310(73.1)

949(60.5)

PM2

  All

20(28.2)

382(38.0)

3(37.5)

1(25.0)

5(4.7)

2(10.0)

18(32.7)

80(42.8)

53(4.5)

386(49.9)

950(27.8)

  <2009

20(28.2)

259(39.1)

NA

1(25.0)

5(4.7)

2(10.0)

18(32.7)

76(41.5)

33(4.0)

244(46.4)

658(26.9)

  >=2009

0

123(35.9)

3(37.5)

NA

NA

NA

NA

4(100)

20(5.6)

142(56.8)

292(30.3)

Mammography3

  All

51(100)

599(96.5)

5(100)

3(100)

98(96.1)

18(100)

37(100)

103(98.1)

731(64.8)

374(96.5)

2019(82.2)

  <2009

51(100)

392(97.8)

NA

3(100)

98(96.1)

18(100)

37(100)

103(98.1)

564(71.4)

269(96.1)

1535(85.9)

  >=2009

0

207(94.1)

5(100)

NA

NA

NA

NA

NA

167(49.4)

105(97.2)

484(72.1)

MRI3

  All

45(88.2)

465(76.7)

5(100)

3(100)

3(3.0)

14(77.8)

35(94.6)

93(93.0)

835(74.0)

252(71.2)

1750(72.8)

  <2009

45(88.2)

276(71.5)

NA

3(100)

3(3.0)

14(77.8)

35(94.6)

93(93.0)

574(72.7)

161(65.5)

1204(69.5)

  >=2009

0

189(85.9)

5(100)

NA

NA

NA

NA

NA

261(77.0)

91(84.3)

546(81.3)

Tamoxifen/Raloxifene3

  All

0

64(10.3)

0

0

10(9.8)

0

0

0

24(2.1)

57(14.7)

155(6.3)

  <2009

0

45(11.2)

NA

0

10(9.8)

0

0

0

22(2.8)

44(15.7)

121(6.8)

  >=2009

0

19(8.6)

0

NA

NA

NA

NA

NA

2(0.6)

13(12.0)

34(5.1)

  1. 1All subjects
  2. 2Subjects without breast cancer; 177 subject with missing data on mastectomy excluded;
  3. 3Subjects without breast cancer and without prophylactic mastectomy; 5 subject with missing data on mammography; 59 missing MRI.